Hypera S.A. (HYPMY)

OTCMKTS · Delayed Price · Currency is USD
4.186
-0.164 (-3.77%)
Mar 4, 2026, 3:27 PM EST
Market Cap2.68B +26.0%
Revenue (ttm)1.31B -10.4%
Net Income154.60M -47.5%
EPS0.24 -47.5%
Shares Outn/a
PE Ratio17.33
Forward PE8.04
Dividend0.15 (3.47%)
Ex-Dividend DateMar 2, 2026
Volume470
Average Volume20,561
Open4.150
Previous Close4.350
Day's Range4.100 - 4.186
52-Week Range3.100 - 5.500
Beta0.25
RSI40.54
Earnings DateMar 12, 2026

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an... [Read more]

Sector Healthcare
Founded 1999
Employees 10,481
Stock Exchange OTCMKTS
Ticker Symbol HYPMY
Full Company Profile

Financial Performance

In 2024, Hypera's revenue was 7.44 billion, a decrease of -5.97% compared to the previous year's 7.91 billion. Earnings were 1.34 billion, a decrease of -18.63%.

Financial numbers in BRL Financial Statements